Daily Stock List
Allied First Bancorp, Inc. (AFBA)
Today we are reporting on Allied First Bancorp, Inc. (AFBA), here at the QualityStocks Daily Newsletter.
Established in 2001, Allied First Bancorp, Inc. operates as the holding company for Allied First Bank. The Bank provides financial services to their customers, and they have a nationwide customer base from their beginnings as a credit union. The also have their local Oswego community that they serve as the community bank in town. Allied First Bancorp, by way of their other subsidiary, Eagle's Nest Marketing Solutions, Inc., provides loan origination call center support to financial institutions. Allied First Bancorp has their headquarters in Oswego, Illinois. The Company's shares trade on the OTC Bulletin Board.
Allied First Bank offers a variety of deposit accounts. These include savings accounts, money market accounts, interest and noninterest bearing demand deposit accounts, and time deposit accounts. The Bank provides secured and unsecured consumer loans. These include automobile and recreational vehicles loans, recreational boat and airplane loans, lines of credit and signature loans, and loans secured by savings deposits, as well as commercial real estate, first mortgage, real estate construction, and credit card loans.
Furthermore, Allied First Bank invests in the United States obligations, securities of different federal agencies, certificates of deposit of insured banks and savings institutions, bankers' acceptances, repurchase agreements, and federal funds. Additionally, they invest in investment grade commercial paper, corporate debt securities, and mutual funds.
As pertains to Business Services, Allied First Bank offers Business Savings, Business Checking, and the Allied First Bank Free Business Checking Account (for businesses that know their business checking account will not have a large volume of items processed every month). The Bank also offers their business customers Community Checking, Business Money Market, Business Sweep Account, Certificates of Deposit, as well as Remote Deposit.
The Bank's online services include Bill Payer, Mobile Banking, Text Message Banking, Payment Manager, and Online Statements. Their Text Message Banking makes it easy for their customers to access account balances and transactions, on their mobile phone.
Allied First Bancorp, Inc. (AFBA), closed Wednesday's trading session at $0.61, up 1.67%, on 4,000 volume with 3 trades. The average volume for the last 60 days is 730 and the stock's 52-week low/high is $0.05/$1.25.
Discovery Gold Corp. (DCGD)
We are highlighting Discovery Gold Corp. (DCGD) today, here at the QualityStocks Daily Newsletter.
Discovery Gold Corp. (formerly Norman Cay Development, Inc.) is an emerging mineral exploration company. Through their 100 percent owned Ghanaian subsidiary company, Discovery Gold Ghana Ltd., (DGG) Discovery Gold owns, subject to final Ghanaian government approval, a 70 percent beneficial interest in an option to acquire the exclusive rights to explore the Edum Banso gold project within the historic and prolific Ashanti Gold Belt located in Ghana, West Africa. The Company has the potential to increase their interest to 95 percent. Discovery Gold lists on the OTCQB.
The Edum Banso gold project covers an area of approximately 8 square miles (20.6 square kilometers) and lies approximately 168 miles (270 kilometers) due west of the city of Accra, the capital of Ghana. The project is near to substantial producing gold mines and recent discoveries of gold deposits.
Discovery Gold has refocused their plan of operations through determining to advance exploration at Edum Banso by promptly (subject to anticipated financing) testing two of the known mineral occurrences and geological structures of the project. These have historically demonstrated the potential to host significant gold deposits.
For Phase I, a pre-drilling exploration program will take place at two selected anomalous gold target areas. This is to identify possible sources of gold anomalies and occurrences for an anticipated drilling program. For Phase 2, the Company would consider a diamond core drilling exploration program of approximately 1,000 to 3,000 meters. This would consist of approximately 7 to 20 drill holes of up to 150 meters deep at a cost of approximately $300,000 to $900,000 (yielding between 400 and 1200 core drill samples being assayed and compiled in a report). This is subject to availability of funds and the results of the pre-drilling exploration program.
Recently, Discovery Gold announced that they completed planning of their pre-drilling exploration program for the Edum Banso Gold Project in Ghana. Their intention is to focus the next round of exploration on two select high-priority anomalous gold targets, Target Zone #1 and Target Zone #5.
They chose these high-priority exploration targets because of previously encouraging results, and in the case of Target Zone #5, its nearness to the unique primary geological feature thought to be associated with the source of gold currently undergoing open pit mining by Golden Star Resources less than 1km from the property border directly to the southeast. Discovery Gold intends to proceed with the first phase of their pre-drilling exploration program in Q4 2012 - as soon as they receive anticipated funding and an exploration services agreement is finalized.
Discovery Gold Corp. (DCGD), closed Wednesday's trading session at $0.51, down 3.77%, on 7,100 volume with 3 trades. The average volume for the last 60 days is 55,381 and the stock's 52-week low/high is $0.12/$0.59.
Phoenix Footwear Group, Inc. (PXFG)
Today we are reporting on Phoenix Footwear Group, Inc. (PXFG), here at the QualityStocks Daily Newsletter.
Founded in 1882, Phoenix Footwear Group, Inc. specializes in quality, comfort, women's footwear. The Company's design focus is on fitting features. They design, develop, market and sell footwear in a broad spectrum of sizes and widths under the brands Trotters® and SoftWalk®. Phoenix Footwear Group's shares trade on the OTC Pink Current Information. The Company has their corporate headquarters in Carlsbad, California.
The Trotters® and SoftWalk® brands primarily sell through department stores, leading specialty and independent retail stores, mail order catalogues and internet retailers. Approximately 650 customers in more than 900 retail locations throughout the United States carry these brands. Phoenix Footwear distributes their products on the internet, directly to consumers, by way of their SoftWalkshoes.com and trotters.com Web sites.
In the SoftWalk® brand, for this fall's styles, the Company has their new Alabama and Abilene products. Alabama is a shootie with a double side gore that sits on top an extra comfortable walking sole. The back collar protects the ankle. SoftWalk's patented eggcrate footbed is the cushioning.
Abilene is a twist on a classic Mary Jane with double Velcro adjustable straps. The padded collar cradles the heel while the cushion vamp helps customize the fit. Likewise, SoftWalk's patented eggcrate footbed is the cushioning. The unique interaction of the design's multi-layers absorbs the stress of standing or walking. It offers cushioned support throughout the whole shoe length. The Company offers their footwear in up to 6 widths and 15 sizes.
The Company's Trotter brand started out in 1935. Their first shoes were moccasins made by Native American craftspeople in Old Town, Maine. This is where Phoenix Footwear still maintains a distribution center. Trotters use the softest leathers, high-tech cushioning and flexible soles. The Company develops a separate last (the form around which the leather is shaped) for each size and width.
Concerning new products in the Trotter line, Phoenix Footwear has two new styles – Leana and Sonia. Leana is based on the popular Liz, features contrasting tassel and piping, and is available in a variety of colors. Sonia features elastic criss-cross straps for a proper fit; it also has a rubber sole for secure all-day walking comfort.
Phoenix Footwear Group, Inc. (PXFG), closed Wednesday's trading session at $0.16, down 8.29%, on 299 volume with 2 trades. The average volume for the last 60 days is 4,318 and the stock's 52-week low/high is $0.08/$0.3999.
Romios Gold Resources, Inc. (RG.V)
Stockhouse reported previously on Romios Gold Resources, Inc. (RG.V), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Established in 1995, Romios Gold Resources, Inc. is a mineral exploration company actively engaging in precious and base metal exploration across North America. The Company has a primary focus on gold, silver and copper. Romios Gold has significant property interests in British Columbia, Ontario, Quebec, as well as Nevada. The Company has their headquarters in Toronto, Ontario. Romios Gold Resources' shares trade on the TSX Venture Exchange.
The Company is undertaking extensive exploration work on their Golden Triangle area properties in British Columbia. These properties sit amongst Galore Creek Mining Corp.'s (GCMC, a NovaGold/Teck Resources' Joint Venture) Galore Creek copper-gold-silver project, Pretium Resources' Brucejack deposit, and Barrick Gold's high-grade gold mine at Eskay Creek. Romios Gold's properties are adjacent to developing infrastructure and the extension of the provincial power grid under construction in the northwestern British Columbia area.
Romios Gold's Newmont Lake Project is situated within 15 km of AltaGas' McLymont River hydropower project. Pertaining to Romios Gold's Trek Project, the Company is developing an NI 43-101 resource at the North Zone. Moreover, the high-grade Scossa Gold Project represents an opportunity for rapid development and low cost production in Nevada. Opportunities for Romios also include continued drilling and resource development for the past-producing La Corne Molybdenum mine site for open pit and rare earth element potential in Quebec. Additionally, Romios Gold is a Joint Venture partner with Mexivada at the Roger Gold Property in the Timmins-Hislop Gold district of Ontario.
This past August, Romios Gold Resources announced the acquisition of approximately 5,700 hectares of mineral tenures within the Golden Triangle area in northwestern British Columbia. The Company now holds approximately 72,000 hectares near Pretium Resources' Brucejack deposit, Barrick Gold's Eskay Creek mine and the Galore Creek Mining Corporation's Galore Creek project.
Today, the Company announced results from their diamond drill program at the '72 Zone. This is the first set of drill results, consisting of 6 of 14 holes drilled this past summer on Romios' Newmont Lake Project, located in the Golden Triangle district. Romios Gold first drill-tested the '72 Zone discovery and incorporated the mineral claims into the Newmont Lake Project in 2011 (Press Release dated October 19, 2011). This past July 786 meters of additional drilling at the '72 Zone through sulphide-bearing and brecciated limestone intersected porphyry dykes and several, concentrated mineralized horizons, containing gold-copper-silver bearing sulphides with anomalous selenium, tellurium, platinum, and palladium.
Romios Gold Resources, Inc. (RG.V), closed Wednesday's trading session at $0.16, up 14.29%, on 88,550 volume. The stock's 52-week low/high is $0.09/$0.35.
Firan Technology Group Corp. (FTG.TO)
We are reporting on Firan Technology Group Corp. (FTG.TO), here at the QualityStocks Daily Newsletter.
Trading on the Toronto Stock Exchange, Firan Technology Group Corp. is an aerospace and defense electronics product and subsystem supplier. The Company has two operating units: FTG Circuits and FTG Aerospace. Firan Technology Group provides a wide spectrum of integrated design and manufacturing services in a one-stop-shop offering. The Company has their corporate headquarters in Toronto, Ontario.
FTG Circuits is a manufacturer of high technology, high reliability printed circuit boards. Their customers are leaders in the aviation, defense, and high technology industries. FTG Circuits has operations in Toronto, Ontario and Chatsworth, California. FTG Aerospace manufactures illuminated cockpit panels, keyboards and sub-assemblies for original equipment manufacturers (OEMs) of aerospace and defense equipment. FTG Aerospace has operations in Toronto, Ontario and Tianjin, China.
Firan Technology Group obtains approximately 70 percent of their revenues from sophisticated printed circuits. All undergo custom-design, with the Company's engineering and quality control groups working closely with the individual customer. Approximately three-quarters of Firan's sales are to the United States. They garner these revenues primarily from the world's leading OEM's and their sub-contract assemblers. The sub-contract segment is the fastest growing market for printed circuit boards.
Last month, Firan Technology Group announced the hiring of Mr. Chris Woodland as Vice President and General Manager of FTG Aerospace, Toronto Division - effective September 6, 2012. Mr. Woodland assumed full responsibility for the performance of the Aerospace Division in Toronto. He has worked at the Robotics Division of MDA Space Missions (formerly Spar Aerospace) for approximately 30 years. His most recent position was as Vice President of Programs. In this position, he was responsible for managing major Canadian space programs such as the Canadarm for the Shuttle, Canadarm2, as well as Dextre for the Space Station as well as related robotic programs for medical, nuclear, science and planetary exploration.
Firan Technology Group will release their Q3 2012 financial results after the close of trading today, October 10, 2012. The Company will host a live conference call on Thursday, October 11 at 11:30am (EDT) to discuss the Q3 2012 financial results. A replay of the call will be available until October 25, 2012 and will be available on the Company's website at www.ftgcorp.com.
Firan Technology Group Corp. (FTG.TO), closed Wednesday's trading at $0.55, down 5.17%, on 7,000 volume. The stock's 52-week low/high is $0.33/$0.80.
Mattson Technology, Inc. (MTSN)
CRWEPicks, DrStockPick, PennyOmega, BestOtc, CRWEWallStreet, StockHotTips, CRWEFinance, and PennyToBuck reported earlier on Mattson Technology, Inc. (MTSN), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Fremont, California, Mattson Technology, Inc. designs, manufactures and markets semiconductor wafer processing equipment used in the fabrication of integrated circuits. The Company is a foremost supplier of plasma and rapid thermal processing equipment to the worldwide semiconductor industry. Mattson Technology operates in three primary product sectors: Dry Strip, Rapid Thermal Processing and Etch. The Company lists on the NASDAQ Global Select market.
Mattson Technology, via manufacturing and design innovation, has produced technologically advanced systems that provide productive and cost-effective solutions for customers fabricating current- and next-generation semiconductor devices. Their strip and RTP equipment use innovative technology to deliver advanced processing performance and productivity gains to semiconductor manufacturers globally for the fabrication of current- and next-generation devices.
The Company is expanding into the etch market with innovative products targeting high volume dielectric etch applications. Mattson is additionally expanding into the millisecond annealing and thermal oxidation markets.
Mattson Technology's customer base includes foundries, memory, and logic device manufacturers. The Company has design and manufacturing centers in the U.S., Canada and Germany. Mattson has sales and support teams in China, France, Germany, Israel, Japan, Korea, Singapore, Taiwan and the U.S.
Last week, the Company announced that they shipped their first follow-on Helios® XP rapid thermal processing (RTP) system to a major foundry customer. The RTP system features premier thermal processing performance and low cost of ownership (CoO). The Helios XP will be used in the foundry's most advanced fab for the volume production and development of leading-edge integrated circuits (ICs).
In addition, last week, Mattson Technology appointed Mr. J. Michael Dodson as Chief Operating Officer (COO) in addition to his existing duties as Chief Financial Officer (CFO). Mr. Dodson joined Mattson Technology as Executive Vice President and CFO in October 2011. He will continue to report to the President and Chief Executive Officer Mr. David L. Dutton on the Company's executive management team. Mr. Dodson's new role encompasses executive oversight of manufacturing operations, finance, administration and corporate marketing.
Mattson Technology, Inc. (MTSN), closed Wednesday's session at $0.85, even for the day, on 191,788 volume with 288 trades. The average volume for the last 60 days is 276,198 and the stock's 52-week low/high is $0.755/$3.30
Helicos BioSciences Corp. (HLCS)
SmarTrend Newsletters reported earlier on Helicos BioSciences Corp. (HLCS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Helicos BioSciences Corp. is a development stage life sciences company that lists on the OTCQB. The Company focuses on genetic analysis technologies primarily in the United States. A life science enterprise, they concentrate on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets. Additionally, Helicos has joined the Personalized Medicine Coalition, looking to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. Founded in 2003, Helicos BioSciences is headquartered in Cambridge, Massachusetts.
The Company's proprietary True Single Molecule Sequencing (tSMS)™, technology allows direct measurement of billions of strands of DNA. This enables scientists to perform experiments and ask questions never before possible. Currently, Helicos is planning the introduction of their first product, the Helicos™ Genetic Analysis System. Their Helicos Genetic Analysis System is used for different scientific applications. These include the analysis of small sample quantities, direct RNA sequencing, RNA and DNA quantitation, as well as ancient DNA sequencing.
The Helicos Genetic Analysis System (based on their tSMS™ technology) enables ultra-highthroughput genetic analysis by directly sequencing single molecules of nucleic acids. The basis of tSMS™ workflow is on a simple, cost effective sample preparation process. This process can easily be scaled and replicated to meet the requirements of large, complex experiments. This overcomes laboratory workflow bottlenecks.
The Helicos Genetic Analysis System will have broad capabilities in basic and translational research, and pharmaceutical R&D. Therefore, the Company believes this will increase the potential for improved drug therapies, personalized medicine and more accurate molecular diagnostics for diseases such as cancer. The Company believes the tSMS™ sequencing by synthesis approach will represent the first comprehensive and universal solution for single molecule genetic analysis. They believe this will substantially lower the cost of individual analyses.
Their Helicos genetic analysis platform consists of the HeliScope single molecule sequencer; the HeliScope analysis engine (an image analysis computer tower); associated reagents (chemicals used in the sequencing process), and disposable supplies.
Helicos BioSciences Corp. (HLCS), closed Wednesday's trading session at $0.035, down 12.50%, on 5,100 volume with 3 trades. The average volume for the last 60 days is 51,049 and the stock's 52-week low/high is $0.021/$0.1599.
AuraSource, Inc. (ARAO)
Today we are highlighting AuraSource, Inc. (ARAO), here at the QualityStocks Daily Newsletter.
AuraSource, Inc. is a technology-driven company focusing on developing and implementing clean energy and mineral processing technologies. A development stage enterprise, the Company is concentrating on the development and production of industrial energy and feedstock used for industrial applications. AuraSource lists on the OTC Bulletin Board. The Company has their corporate headquarters in Chandler, Arizona, as well as a China Operation Office in the Chaoyang District, Beijing.
A Nevada corporation, AuraSource is beginning operations with two hydrocarbon clean fuel technologies: AuraCoal™ and AuraFuel™. The Company also has their mineral processing technology: AuraMetal™. All of these are environment-friendly.
AuraSource developed the AuraCoal™ process. This is a patent pending technology to remove sulfur and ash from coal during a pre-combustion processing stage. This process reduces energy costs and all but eliminates harmful emissions. This proprietary clean coal technology produces a hydrocarbon fuel. This fuel contains only trace amounts of sulfur and ash. It is a low-cost alternative to oil or natural gas. AuraSource will invest in AuraCoal™ plants and provide distribution of the coal based clean industrial fuel products.
AuraSource has licensed the proprietary hydrocarbon clean fuel technology AuraFuel™. It utilizes a low temperature catalytic process to convert oil shale, asphalt shale and low-ranking coal to hydrocarbon clean fuel products in a highly efficient manner. The Company developed the AuraMetal™ process based on their grinding and separation technologies. This technology separates commercially valuable minerals from their ores economically and efficiently. It has an extensive application in metal beneficiation such as hematite that cannot undergo concentration through magnetic separation.
AuraSource's intellectual property (IP) portfolio includes ultrafine grinding and separation processes. These processes enable the production of high value feedstock and a further reduction in cost for several industrial applications.
Recently, AuraSource announced that they formed a strategic partnership with China Xinxing Cathy International Group. This partnership is to joint research and develop ultra-low ash coal, import iron ore and process minerals. As part of the strategic partnership cooperation, AuraSource also entered into a joint development agreement with Xinxing Ductile Iron Pipes Co., Ltd. for a larger capacity slurry particles centrifugal separator. Xinxing is one of the largest producers of ductile cast iron pipes and steel gratings in the world. Xinxing will use this technology for pre-combustion ash removal and hematite beneficiation for their production of steel.
AuraSource, Inc. (ARAO), closed at $0.40, even for the day, on 1,750 volume with 1 trade. The average volume for the last 60 days is 1,829 and the stock's 52-week low/high is $0.045/$0.65.
GlobalWise Investments, Inc. (GWIV)
The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.55, up 22.22%, on 5,925 volume with 4 trade. The stock’s average daily volume over the past 60 days is 6,401, and its 52-week low/high is $0.43/$1.87.
GlobalWise Investments, Inc. announced a new channel partnership with 30-year business process solutions integration/implementation firm Level Seven, opening up another huge marketing channel for GlobalWise's poweful cloud-based Enterprise Content Management platform. The vast competencies built up by Level Seven pursuing the cutting edge of complex business management software solutions that span digital and traditional media, will be significantly enhanced through the addition of the Intellivue™ suite to their cloud-based portfolio of offerings, as this comprehensive, value driven document management solution (requiring minimal setup and training) is a perfect natural extension of Level Seven's existing service offerings.
GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.
GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.
The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.
GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer
GlobalWise Investments Company Blog
GlobalWise Investments News:
GlobalWise Announces New Channel Partnership With Level Seven
GlobalWise Announces Appointment of Kendall D. Gill to Chief Financial Officer Position
MissionIR Features GlobalWise in Exclusive Interview Featuring CEO William Santiago
Teletouch Communications, Inc. (TLLE)
The QualityStocks Daily Newsletter would like to spotlight Teletouch Communications, Inc. (TLLE). Today, Teletouch Communications, Inc. closed trading at $0.48, up 9.59%, on 2,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 25,632, and its 52-week low/high is $0.253/$0.89.
Teletouch Communications, Inc. (TLLE) offers a comprehensive suite of wireless telecommunications solutions, including cellular, GPS-telemetry, and wireless messaging. Founded in 1964, the company provides its products and services to consumers, businesses, and government agencies, operating a chain of 11 retail and authorized agent stores, in conjunction with its direct sales force, call center operations, and various retail eCommerce websites.
Through its wholly owned subsidiary, Progressive Concepts, Teletouch operates a national distribution business, PCI Wholesale, primarily serving Tier-1 (AT&T, T-Mobile, Verizon, Sprint) cellular carrier agents, Tier-2, Tier-3, and rural carriers, as well as auto dealers and smaller consumer electronics retailers. The subsidiary's international sales coverage includes Canada, Mexico, Brazil, Singapore, and China.
The company is currently focusing on growing its core wholesale distribution business. The business plan being executed includes selling non-core corporate assets and reviewing potential acquisition opportunities. Operators and retailers of all sizes are seeking new sources of revenue at lower costs, creating a large opportunity to provide great products and value-added distribution capabilities at competitive prices.
Teletouch's management team has extensive experience in financing, acquiring, and operating retail, wireless and other related companies. Robert McMurrey, Chairman and CEO, guided Teletouch's original external expansion with the completion of over 15 acquisitions to date. Today, the company supports over 60,000 wireless customers, leveraging its long-standing relationships and global presence to drive future earnings growth. Disclaimer
Teletouch Communications, Inc. Blog
Teletouch Communications, Inc. News:
Teletouch Returns as Official Cellular Sponsor for the 10th Anniversary ESPN 2012 Bell Helicopter Armed Forces Bowl
Teletouch Announces Distribution Agreement with Unimax Communications for Sales of UMX Branded Cellular Handsets in North America
Teletouch Reports Fiscal Year 2012 Results
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.25, up 0.40%, on 25,550 volume with 10 trades. The stock’s average daily volume over the past 60 days is 108,283, and its 52-week low/high is $0.21/$0.835.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corp Discusses Its New Cellular Reprogramming Technology in View of the Recent Award of the Nobel Prize in Physiology or Medicine
International Stem Cell Corp to Participate in Upcoming Investor Conference
International Stem Cell Corp Granted Key Patent for Liver Disease Program
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.75, even for the day, on 300 volume with 1 trade. The stock’s average daily volume over the past 60 days is 78, and its 52-week low/high is $0.06/$3.15.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics Announces Strategic Financing With Platinum Long Term Growth Fund
VistaGen CEO Issues Update Letter to Stockholders
VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity
GlobalWise Investments and its wholly owned subsidiary Intellinetics, a leading-edge technology company focused on the design, implementation, and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, just announced a new channel partnership with Level Seven.
Level Seven (www.lvlsvn.com) has accumulated more than three decades of experience integrating and implementing business process solutions. The company provides software tools to small, medium and enterprise customers with compelling advantages by continually pursuing the latest technology. Level Seven solves its clients’ business challenges by translating insight into relevant processes, content, and experiences that are delivered, measured, and optimized across channels, platforms, and devices.
“The relationship with Level Seven will provide GlobalWise another expansive marketing channel for our cloud-based ECM software platform,” commented William “BJ” Santiago, CEO of GlobalWise. “Level Seven has a long and rich history in implementing complex business management software solutions that cross digital and traditional media. I am proud they have selected Intellivue™ to be added to their cloud-based software portfolio of services.”
Lisa Locklear, Business Development Director of Level Seven, stated, “Level Seven is thrilled to add the Intellivue™ suite to its offering. Enterprise Content Management offers a natural extension to the technology and business services that we provide to our clients. As a hosted service, Intellivue™ can also provide our clients with a value driven document management solution that requires minimal setup and training. The different hosting and workflow options that Intellivue™ offers will allow us to implement and scale based on what’s most important for each individual client and their budget.”
To learn more about GlobalWise Investments, visit www.GlobalWiseInvestments.com
VistaGen Therapeutics is best known for having developed a versatile stem cell technology platform which can be used to produce superior testing options for new drug candidates, with the potential of saving the drug industry millions or even billions of dollars. But the company also has entered the high-dollar world of neuropathic pain management with the clinical development of AV-101, its small molecule drug candidate for the treatment of pain, and possibly depression and other neurological disorders.
Although the sensation of pain is an important protective mechanism for the body, warning of injuries and disease, it can sometimes persist long after an injury has healed, due to errant nerve impulses. Such chronic neuropathic pain can go on for months, and, in some cases, can itself be detrimental, causing organ damage or leading to a persistent pain state.
The global neuropathic pain market, though competitive, is huge, estimated at $4.8 billion in 2010 and expected by some to grow to $10 billion by 2018, representing an annual growth rate of over 9%. The increasing number of people facing diseases related to neuropathic pain will continue to fuel market growth. Today, the market is dominated by Pfizer’s Lyrica and Eli Lilly’s Cymbalta, with relatively few drugs in total currently approved for the treatment of neuropathic pain.
VistaGen’s AV-101 is a novel, orally available prodrug that is unique in its ability for rapid and efficient transport across the blood-brain barrier, where it converts in form to an effective pain blocker. Specifically, AV-101 is converted in the brain into an active metabolite, 7-chlorokynurenic acid (7-Cl-KYNA), which is an antagonist of the N-methyl-D-aspartate (NMDA) receptors. 7-Cl-KYNA is a synthetic analogue of kynurenic acid, a naturally occurring CNS regulatory compound, and is one of the most potent and selective blockers of the regulatory GlyB-site of the NMDA receptor.
AV-101 is completing Phase 1 clinical development in the U.S., under an active Investigational New Drug (IND) application on file at the U.S. FDA.
For additional information, visit the company’s website at www.VistaGen.com
MusclePharm, a Colorado-based maker of nutritional supplements for athletes and active health-conscious consumers, has enjoyed revenue growth based upon the acceptance of its products but also on the strong partnerships the company has managed to forge with sports organizations and distributors. On the product side, MusclePharm is differentiated in the marketplace by the fact that it works closely with scientists, doctors, and athletes to test and verify the positive effects of its many specially designed nutritional products, products that are 100% free of any banned substances. Anyone looking to safely enhance their athletic performance can depend upon the company’s formulations, proven out at the company’s 40,000 square foot state-of-the-art athletic and testing facility.
On the partnership side, MusclePharm has developed critical links with distributors and the athletic community, ensuring that the unmatched benefits of its research are known and available to its target market.
• UFC, Ultimate Fighting Championship (Official Nutritional Supplement Provider)
• Reebok CrossFit Games
• Cincinnati Reds Baseball
• Bally Total Fitness
• Dick’s Sporting Goods
• The Vitamin Shoppe
• Vitamin World
• 24Hour Fitness
• Smoothie King
• Europa Sports Products
• Eurpac Service Company
• Sportika Export
MusclePharm has also partnered with Wounded Warrior Project, a national charitable organization with a range of programs to raise public awareness of, and to assist, this nation’s injured service members.
The success of MusclePharm’s approach is seen in its rapid revenue growth over the past few years, going from $3 million in 2010 to $17 million in 2011, and standing at over $30 million for just the first half of 2012.
For additional information, visit www.MusclePharm.com
In the distant past, being fat was considered a good thing, a sign of success and prosperity in a world where food was hard to come by. In some parts of the world, this is still the case. And yet, as far back as ancient Greece, obesity was recognized as a potential health risk, contributing to other recognized diseases. As advances in technology and distribution increased the food supply, the size of the average person increased, with industrialization hastening the process. Today, the modern American diet and reduction in physical activity has made obesity a front page issue, and even the government is taking steps to discourage overeating and high-calorie foods.
Skinny Nutritional is on the front lines of this movement, with its Skinny Water brand becoming one of the first zero-calorie enhanced water and the first zero sodium sports drink. It sounds like a simple idea, but it’s far from a simple process. The health water market is demanding and competitive, and putting together a product that has unmatched health features along with great taste is a formidable challenge.
Skinny Water is unique in its combination of health benefits and consumer appeal:
• Great taste, with purified water and 100% natural flavors
• No artificial colors or preservatives
• Zero sugar, zero carbs, zero calories, and zero sodium
• Vitamins, Electrolytes, and Antioxidants, formulated in different combinations for different effects
Getting a great product out to the marketplace is yet another challenge. The company has been aggressive in its distribution efforts, knowing that, once people tried the product, they would like it. Skinny Water is now sold in over 14,000 retail stores across the country, and is handled by both domestic and international distributors. Functional names such as Crave Control (appetite suppressant), Hi-Energy (natural energy boost), Wake-Up (240% daily Vitamin C) and Shape (electrolytes + antioxidants), have helped drive the increase in sales. And new offerings, such as Skinny Water pH+, designed to improve acid-alkaline balance in the body, keep Skinny Water on the leading edge of market demand.
For additional information, visit the company’s websites at www.SkinnyWater.com
Today's Top 3
The QualityStocks Public Company Sponsor News